Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Compare the resting energy expenditure of COVID-19 patients (obese or non-obese) in intensive care unit with mechanical ventilation to a control group of non-COVID-19 intensive care patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| COVID intensive care unit |
| ||
| intensive care unit |
| ||
| obesity |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| indirect calorimetry | Diagnostic Test | to determine and compare the resting energy expenditure of each group |
|
| Measure | Description | Time Frame |
|---|---|---|
| The resting energy expenditure (in Kcal / 24h) measured by indirect calorimetry during the stay in intensive care. | baseline and 3 months later |
Not provided
Not provided
Inclusion Criteria:
For the Ambulatory Obese Control Group, the inclusion criteria are:
For the COVID Group and the Resuscitation Control Group, the inclusion criteria are:
Only for the COVID Group:
Only for the Resuscitation Control Group:
- Patient hospitalized in intensive care for an indication other than an infectious cause.
Exclusion Criteria:
Non-inclusion criteria for the Ambulatory Obese Control Group:
The non-inclusion criteria for the COVID Group and the Resuscitation Control Group:
Only for the COVID Group:
Not provided
Not provided
Not provided
Patients admitted to resuscitation under mechanical ventilation and who have benefited from a first indirect calorimetry measurement via COSMED Q NRG within 48 hours after their admission are identified by the physicians of the resuscitation department. If these patients meet all the inclusion criteria, they will be notified to the center's investigators so that the latter can take the necessary steps to inform the patient or the confidential person about the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Vincent FLORENT, MD, PhD | Centre Hospitalier Arras | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Arras general hospital | Arras | 62000 | France |
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D009765 | Obesity |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |